SCHEMBL6077929

SCHEMBL6077929

CC1NC(=O)C2CSC(=O)N2C1=O

nearest known ligand 0.37

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
HDAC4 P56524 2/20 0.36
HDAC1 Q13547 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6076907 0.78 CYP2C9 (0.41)
SCHEMBL6078396 0.78 HDAC4 (0.40) LMNAHDAC4HDAC1
SCHEMBL6077888 0.76 MMP1 (0.35)
SCHEMBL6077657 0.74 GAA (0.45) LMNAGAA
SCHEMBL6078844 0.73 ALDH1A1 (0.46) POLBGAA
SCHEMBL6078979 0.69
SCHEMBL6079130 0.67
SCHEMBL6078230 0.66
SCHEMBL6078345 0.64 HDAC6 (0.35)
SCHEMBL14612064 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7022317-B2 Heterocyclic derivatives of 2-oxothiazolidine-4-carboxylic acid, and use as active photoprotective agents L'OREAL (FR) 2006-04-04 US claimed
US-20050129635-A1 Novel heterocyclic derivatives of 2-oxothiazolidine-4-carboxylic acid, and use as active photoprotective agents L'OREAL S.A. (FR) 2005-06-16 US claimed
US-7022317-B2 Heterocyclic derivatives of 2-oxothiazolidine-4-carboxylic acid, and use as active photoprotective agents L'OREAL (FR) 2006-04-04 US disclosed
US-20050129635-A1 Novel heterocyclic derivatives of 2-oxothiazolidine-4-carboxylic acid, and use as active photoprotective agents L'OREAL S.A. (FR) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050129635-A1 Novel heterocyclic derivatives of 2-oxothiazolidine-4-carboxylic acid, and use as active photoprotective agents CUTA, OGDH, TYR LMNA 3284/4885POLB 1014/4885GAA 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.